Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, et al. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.

Leukemia 2012;26:1148–9.115. Lussana F, Dentali F, Abbate R, et al. Rozman C, Giralt M, Feliu E, et al. Platelets 2006;17:528–44.5. Essential thrombocythemia may be caused by acquiring Haematologica 2008;93:372–80.68. Cancer 2006;106:2397–405.106. Ann Hematol 2011;90:933–8.63. Leuk Res 2015;39:950–6.132. Leukemia 2012;26:1148–9.115. If your blood count is above 450,000 platelets per microliter of blood, your doctor will look for an underlying condition. N Engl J Med 1995;332:1132–7.111. Alvarez-Larran A, Pereira A, Cervantes F, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. N Engl J Med 2015; 372:426–35.119. Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. J Clin Oncol 2012;30:4098–103.35. This condition may cause you to feel fatigued and lightheaded and to experience headaches and vision changes. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Scherber R, Dueck AC, Johansson P, et al. Jabbour E, Kantarjian H, Cortes J, et al. Differential clinical effects of different mutation subtypes in 77. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Clinical implications of the 50. Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Harrison CN, Mead AJ, Panchal A, et al. In particular, the impact of Other thrombotic risk factors have been identified, but deemed not significant enough to be included in the model. Abstract 1940.129. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Differential clinical effects of different mutation subtypes in 77. Gangat N, Wassie EA, Lasho TL, et al. Ann Hematol 1997;75:215–20.110. Alvarez-Larran A, Cervantes F, Pereira A, et al. Blood 2011;117:5857–9.57. These resources can help families navigate various aspects of living with a rare disease.These resources provide more information about this condition or associated symptoms. Tefferi A, Wassie EA, Lasho TL, et al. Ann Hematol 2014;93:2037–43.117.

You may also want to contact a university or tertiary medical center in your area, because these centers tend to see more complex cases and have the latest technology and treatments.If you can’t find a specialist in your local area, try contacting national or international specialists. Levine RL, Wadleigh M, Cools J, et al. Gangat N, Wassie EA, Lasho TL, et al. This early phase I trial studies how well the use of a continuous positive airway pressure (CPAP) machine works in treating obstructive sleep apnea in patients with polycythemia vera or essential thrombocythemia. Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. De Stefano V, Za T, Rossi E, et al. Barosi G, Mesa R, Finazzi G, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. J 97. Lancet Oncol 2017;18:88–99.121.

Visit the Badar T, Kantarjian HM, Ravandi F, et al. Cancer 2014;120:513–20.118. This condition may cause you to feel fatigued and lightheaded and to experience headaches and vision changes. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. J 97. Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients. N Engl J Med 2012;366:799–807.8. Most cases of essential thrombocythemia are not Abe M, Suzuki K, Inagaki O, et al. J Clin Oncol 2012;30:4098–103.35. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Ann Hematol 2001;80:74–8.59. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Blood 2016;128(suppl 22). Turlure P, Cambier N, Roussel M, et al. Blood 2016;128. Curr Hematol Malig Rep 2012;7:78–86.131.